PA
TBPH icon

PharVision Advisers’s Theravance Biopharma TBPH Stock Holding History

PharVision Advisers’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,751
Closed -$157K – 993
2025
Q3 		$157K Buy
+10,751
New +$136K 0.09% 561

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

PharVision Advisers's TBPH Position: Q4 2025 in Review

PharVision Advisers sold out of Theravance Biopharma (TBPH) in Q4 2025, closing a stake of 10,751 shares — an estimated $157K sold.

PharVision Advisers first reported a position in TBPH in Q3 2025 and held it in 1 quarter. The position peaked at $157K in Q3 2025. 169 funds tracked by Wall St. Rank hold TBPH as of Q4 2025.

  • PharVision Advisers reported no remaining Theravance Biopharma position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 10,751 Theravance Biopharma shares in Q4 2025, an estimated $157K.
  • PharVision Advisers first reported a position in Theravance Biopharma in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's Theravance Biopharma position peaked at $157K in Q3 2025.
  • 169 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.